Combination of Arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma

Medhi Wangpaichitr, Chunjing Wu, Gregory Bigford, George Theodoropoulos, Min You, Ying Ying Li, Javier Verona-Santos, Lynn G Feun, Dao Nguyen, Niramol Savaraj

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

In the present study we present data to show that certain tumor cells including malignant pleural mesothelioma (MPM) cells do not express argininosuccinate synthetase (ASS), and thus are unable to synthesize arginine from citrulline. Exposure of these ASS-negative cells to the arginine degrading enzyme, arginine deiminase (ADIPEG20), for 72 h results in significant increases in cleaved caspase-3. Importantly, this apoptotic signal is further strengthened by the addition of TNF-related apoptosisinducing ligand (TRAIL). Using flow cytometry, we showed that the combination treatment (ADI-PEG20 at 50 ng/ml and TRAIL at 10 ng/ml) for 24 h resulted in profound cell death with 67% of cells positive for caspase-3 activity, while ADIPEG20 alone or TRAIL alone resulted in only 10-15% cell death. This positive amplification loop is mediated through the cleavage of proapototic protein "BID". Conclusion: Our work represents a new strategy for treating patients with malignant pleural mesothelioma using targeted molecular therapeutics based on selected tumor markers, thus avoiding the use of potentially cytotoxic chemotherapy.

Original languageEnglish
Pages (from-to)6991-6999
Number of pages9
JournalAnticancer Research
Volume34
Issue number12
StatePublished - Jan 1 2014

Fingerprint

Mesothelioma
Arginine
Argininosuccinate Synthase
Ligands
Caspase 3
Cell Death
Citrulline
Therapeutics
Tumor Biomarkers
Flow Cytometry
Drug Therapy
Enzymes
Neoplasms
Proteins
Malignant Mesothelioma

Keywords

  • Arginine deprivation
  • Mesothelioma
  • TNF-related apoptosis-inducing ligand (TRAIL).

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combination of Arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma. / Wangpaichitr, Medhi; Wu, Chunjing; Bigford, Gregory; Theodoropoulos, George; You, Min; Li, Ying Ying; Verona-Santos, Javier; Feun, Lynn G; Nguyen, Dao; Savaraj, Niramol.

In: Anticancer Research, Vol. 34, No. 12, 01.01.2014, p. 6991-6999.

Research output: Contribution to journalArticle

Wangpaichitr, M, Wu, C, Bigford, G, Theodoropoulos, G, You, M, Li, YY, Verona-Santos, J, Feun, LG, Nguyen, D & Savaraj, N 2014, 'Combination of Arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma', Anticancer Research, vol. 34, no. 12, pp. 6991-6999.
Wangpaichitr M, Wu C, Bigford G, Theodoropoulos G, You M, Li YY et al. Combination of Arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma. Anticancer Research. 2014 Jan 1;34(12):6991-6999.
Wangpaichitr, Medhi ; Wu, Chunjing ; Bigford, Gregory ; Theodoropoulos, George ; You, Min ; Li, Ying Ying ; Verona-Santos, Javier ; Feun, Lynn G ; Nguyen, Dao ; Savaraj, Niramol. / Combination of Arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma. In: Anticancer Research. 2014 ; Vol. 34, No. 12. pp. 6991-6999.
@article{c0046534e0044b7ca61683588250bcf7,
title = "Combination of Arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma",
abstract = "In the present study we present data to show that certain tumor cells including malignant pleural mesothelioma (MPM) cells do not express argininosuccinate synthetase (ASS), and thus are unable to synthesize arginine from citrulline. Exposure of these ASS-negative cells to the arginine degrading enzyme, arginine deiminase (ADIPEG20), for 72 h results in significant increases in cleaved caspase-3. Importantly, this apoptotic signal is further strengthened by the addition of TNF-related apoptosisinducing ligand (TRAIL). Using flow cytometry, we showed that the combination treatment (ADI-PEG20 at 50 ng/ml and TRAIL at 10 ng/ml) for 24 h resulted in profound cell death with 67{\%} of cells positive for caspase-3 activity, while ADIPEG20 alone or TRAIL alone resulted in only 10-15{\%} cell death. This positive amplification loop is mediated through the cleavage of proapototic protein {"}BID{"}. Conclusion: Our work represents a new strategy for treating patients with malignant pleural mesothelioma using targeted molecular therapeutics based on selected tumor markers, thus avoiding the use of potentially cytotoxic chemotherapy.",
keywords = "Arginine deprivation, Mesothelioma, TNF-related apoptosis-inducing ligand (TRAIL).",
author = "Medhi Wangpaichitr and Chunjing Wu and Gregory Bigford and George Theodoropoulos and Min You and Li, {Ying Ying} and Javier Verona-Santos and Feun, {Lynn G} and Dao Nguyen and Niramol Savaraj",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "34",
pages = "6991--6999",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Combination of Arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma

AU - Wangpaichitr, Medhi

AU - Wu, Chunjing

AU - Bigford, Gregory

AU - Theodoropoulos, George

AU - You, Min

AU - Li, Ying Ying

AU - Verona-Santos, Javier

AU - Feun, Lynn G

AU - Nguyen, Dao

AU - Savaraj, Niramol

PY - 2014/1/1

Y1 - 2014/1/1

N2 - In the present study we present data to show that certain tumor cells including malignant pleural mesothelioma (MPM) cells do not express argininosuccinate synthetase (ASS), and thus are unable to synthesize arginine from citrulline. Exposure of these ASS-negative cells to the arginine degrading enzyme, arginine deiminase (ADIPEG20), for 72 h results in significant increases in cleaved caspase-3. Importantly, this apoptotic signal is further strengthened by the addition of TNF-related apoptosisinducing ligand (TRAIL). Using flow cytometry, we showed that the combination treatment (ADI-PEG20 at 50 ng/ml and TRAIL at 10 ng/ml) for 24 h resulted in profound cell death with 67% of cells positive for caspase-3 activity, while ADIPEG20 alone or TRAIL alone resulted in only 10-15% cell death. This positive amplification loop is mediated through the cleavage of proapototic protein "BID". Conclusion: Our work represents a new strategy for treating patients with malignant pleural mesothelioma using targeted molecular therapeutics based on selected tumor markers, thus avoiding the use of potentially cytotoxic chemotherapy.

AB - In the present study we present data to show that certain tumor cells including malignant pleural mesothelioma (MPM) cells do not express argininosuccinate synthetase (ASS), and thus are unable to synthesize arginine from citrulline. Exposure of these ASS-negative cells to the arginine degrading enzyme, arginine deiminase (ADIPEG20), for 72 h results in significant increases in cleaved caspase-3. Importantly, this apoptotic signal is further strengthened by the addition of TNF-related apoptosisinducing ligand (TRAIL). Using flow cytometry, we showed that the combination treatment (ADI-PEG20 at 50 ng/ml and TRAIL at 10 ng/ml) for 24 h resulted in profound cell death with 67% of cells positive for caspase-3 activity, while ADIPEG20 alone or TRAIL alone resulted in only 10-15% cell death. This positive amplification loop is mediated through the cleavage of proapototic protein "BID". Conclusion: Our work represents a new strategy for treating patients with malignant pleural mesothelioma using targeted molecular therapeutics based on selected tumor markers, thus avoiding the use of potentially cytotoxic chemotherapy.

KW - Arginine deprivation

KW - Mesothelioma

KW - TNF-related apoptosis-inducing ligand (TRAIL).

UR - http://www.scopus.com/inward/record.url?scp=84918523726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918523726&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 6991

EP - 6999

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -